New focus on nanopore with Stratos Genomics buy

22 May 2020

2019_biotech_genetic_test_biomarker_targeted_big

In a move aimed at boosting development of its nanopore sequencing technology, Swiss cancer giant Roche (ROG: SIX) has bought out early-stage sequencing expert Stratos Genomics.

The two companies started working together in 2014, after Roche made a strategic investment to support development of single molecule sequencing of DNA fragments.

In the same year, as part of its push into DNA sequencing technology, Roche announced plans to buy California’s Genia Technologies for up to $350 million. The firm was eventually incorporated into the Roche Sequencing Unit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK